AGLYCOSYLATED ANTI-Bb ANTIBODIES AND USES THEREOF
OwnerRekha Bansalinventor
Life of this patent
Estimating the term…
Abstract
An aglycosylated humanized anti-Bb (AAfBb) antibody or antigen binding fragment thereof includes a modification at a conserved N-linked site in the CH2 domains of an Fc portion of the antibody or antigen binding fragment thereof.
Claims20
An aglycosylated humanized anti-factor Bb (AAfBb) antibody or antigen binding fragment thereof, comprising a modification at a conserved N-linked site in the CH2 domains of an Fc portion of the antibody or antigen binding fragment thereof.
A method for inhibiting alternative complement pathway in a subject in need thereof, comprising:
- administering to the subject a therapeutically effective amount of an aglycosylated humanized anti-Bb (AAfBb) antibody or antigen binding fragment thereof, wherein the AAfBb antibody or antigen binding fragment thereof has a heavy chain variable domain including 3CDRs having the amino acid sequences of SEQ ID NO:
- 2, SEQ ID NO:
- 3 and SEQ ID NO:
- 4 and a light chain variable domain including 3CDRs having amino acid sequences of SEQ ID NO:
- 19, SEQ ID NO:
- 20, and SEQ ID NO:
- 21.
A method of ameliorating complement-mediated diseases in a subject in need thereof, the method comprising:
- administering to the subject a therapeutically effective amount of an aglycosylated humanized anti-Bb (AAfBb) antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof includes a mutation of N297 using EU Kabat numbering at the conserved N-linked sites in the CH2 domains of an Fc portion of the AAfBb antibody or antigen binding fragment thereof, wherein the mutation prevents glycosylation at the site and binding to Fc receptors on cells.
Dependencies are inferred from the claim text.